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Abstract
Liposomes containing the acidic phospholipid phosphatidylserine (PS) have been shown to avidly interact with proteins
involved in blood coagulation and complement activation. Membranes with PS were therefore used to assess the shielding
properties of poly(ethylene glycol 2000)-derivatized phosphatidylethanolamine (PE-PEG2000) with various acyl chain lengths
on membranes containing reactive lipids. The desorption of PE-PEG2000 from PS containing liposomes was studied using an
in vitro assay which involved the transfer of PE-PEG2000 into multilamellar vesicles, and the reactivity of PS containing
liposomes was monitored by quantifying interactions with blood coagulation proteins. The percent inhibition of clotting
activity of PS liposomes was dependent on the PE-PEG2000 content. 1,2-Distearoyl-sn-glycero-3-phosphoethanolamine
(DSPE)-PEG2000 which transferred out slowly from PS liposomes was able to abolish s 80% of clotting activity of PS
liposomes at 15 mol%. This level of DSPE-PEG2000 was also able to extend the mean residence time of PS liposomes from
0.2 h to 14 h. However, PE-PEG2000 with shorter acyl chains such as 1,2-dimyristyl-sn-glycero-3-phosphoethanolamine-
PEG2000 were rapidly transferred out from PS liposomes, which resulted in a 73% decrease in clotting activity inhibition and
45% of administered intravenously liposomes were removed from the blood within 15 min after injection. Thus, PS facilitates
the desorption of PE-PEG2000 from PS containing liposomes, thereby providing additional control of PEG release rates from
membrane surfaces. These results suggest that membrane reactivity can be selectively regulated by surface grafted PEGs
coupled to phosphatidylethanolamine of an appropriate acyl chain length. ß 2002 Elsevier Science B.V. All rights reserved.
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atized phosphatidylethanolamine; MPS, mononuclear phagocytic system; PS, phosphatidylserine; DOPS, 1,2-dioleoyl-sn-glycero-3-[phos-
pho-L-serine] ; PC, phosphatidylcholine; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; POPE-PEG2000, 1-palmitoyl-2-oleoyl-sn-glyc-
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1. Introduction
Phosphatidylserine (PS) has long been recognized
for its involvement in the blood coagulation cascade
reactions [1]. Recently, solid tumor regression
through selective thrombosis of tumor blood vessels
has been achieved using the ‘coaguligand’ which is a
truncated tissue factor linked to a monoclonal anti-
body targeted against the tumor vasculature [2,3].
With the ability of PS containing membranes to
bind the high a⁄nity clotting factors and subse-
quently activate the blood coagulation reactions, de-
signing a liposomal carrier for PS may potentially
have similar therapeutic applications in anticancer
therapy. However, several obstacles have to be over-
come in the development of a PS liposomal formu-
lation capable of triggering selective tumor thrombo-
sis.
First, the thrombogenic PS liposome surface
should be protected in the bloodstream to prevent
disseminated intravenous coagulation (DIC). Also,
including reactive lipid species such as the negatively
charged PS in liposomes enhances mononuclear
phagocytic system (MPS) recognition, and causes
rapid elimination of the liposomes from blood-
stream, resulting in less accumulation of the lipo-
somes in the target site [4,5]. It is widely known
that the poly(ethylene glycol) (PEG) polymer conju-
gated to the liposome surface can be used as a steric
barrier against plasma protein binding and cellular
surface interactions at a surface density of 5 mol% to
extend the circulation times of neutral liposomes
composed of phosphatidylcholines (PC), sphingo-
myelins and cholesterol (Chol) [6,7]. However, this
surface density of 5 mol% PEG is not e¡ective in
protecting the PS containing liposomes [6,8]. Re-
cently, we have been able to extend the circulation
longevity of 10% 1,2-dioleoyl-sn-glycero-3-[phospho-
L-serine] (DOPS) liposomes by incorporating s 10
mol% 1,2-distearoyl-sn-glycero-3-phosphoethanol-
amine-N-[poly(ethylene glycol) 2000] (DSPE-
PEG2000), indicating that elevated levels of DSPE-
PEG2000 are required to e¡ectively protect PS lipo-
somes from high a⁄nity, PS-mediated plasma pro-
tein interactions [9].
Once the liposomes have reached the target site,
i.e. tumor blood vessels, exposure of the thrombo-
genic PS liposome surface is necessary to trigger the
blood coagulation reactions. Thus, the thrombogenic
PS liposomes need to be designed such that they are
only temporarily protected by PEG-conjugated lipids
(PEG-lipids) to prevent DIC in the general circula-
tion. The transformation of the well-protected PS
liposome surface to one that is reactive toward var-
ious clotting factors is dependent on the retention of
the steric PEG barrier on the PS liposome surface. It
has been shown that 5 mol% 1-palmitoyl-2-oleoyl-sn-
glycerol-3-phosphatidylethanolamine (POPE)-
PEG2000 is less e¡ective in extending the circulation
time of 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC)/Chol liposomes than the same mole percent-
age of DSPE-PEG2000 present in the liposomes [10].
This is mainly due to the increased exchange of the
entire poly(ethylene glycol 2000)-derivatized phos-
phatidylethanolamine (PE-PEG2000) conjugate out
of the DSPC/Chol liposome when POPE was used
as the lipid anchor [10]. Other reports have demon-
strated that the rate of PEG-lipid exchange is depen-
dent on the acyl chain composition [11^14]. The ex-
changeability of PEG-lipids in and out of membrane
bilayers has also been demonstrated in studies where
the acquisition of the PEG barrier on liposome sur-
face was achieved by the spontaneous insertion of
free micellar PEG-lipids into pre-formed liposomes
[15^17]. This PEG-lipid exchange phenomenon has
been utilized to provide controlled drug release for
improved therapeutic activity [18], and controlled in-
tracellular delivery for antisense oligonucleotides
[19].
The aim of our present study is to use PEG2000-
conjugated PEs with acyl chain lengths varying from
14 to 18 carbons to investigate the kinetics of PE-
PEG transfer into and out of 10% DOPS liposomes,
as well as how this a¡ects PS membrane surface re-
activity. These properties were evaluated by deter-
mining: (1) the clotting activity of 10% DOPS lipo-
somes as PE-PEGs exchanged in and out of the
membrane, and (2) the plasma levels of 10% DOPS
liposomes stabilized by PE-PEGs following intrave-
nous administration. We have measured the level of
PE-PEGs in PS liposomes during the transfer pro-
cesses, and found that the degree of protection of the
PS liposome was correlated to the PE-PEG levels in
the liposomes. We demonstrate here that PE-PEG2000
with a lipid anchor of appropriate chain length can
be used to regulate membrane surface reactivity of
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liposomes containing reactive lipid species such as
PS. This may have important implications in (1)
the delivery of biologically active lipids, and (2) the
design of liposomes containing reactive surfaces for
therapeutic applications, and, in particular, the ap-
plication pursued here towards the development of
liposomes that can induce tumor-speci¢c thrombosis
triggered by controlled exposure to PS, a lipid known
to initiate the blood coagulation cascade.
2. Materials and methods
2.1. Materials
All lipids were obtained from Avanti Polar Lipids
except for DSPC, [3H]DSPE-PEG2000, [3H]-1,2-dipal-
mitoyl-sn-glycero-3-phosphoethanolamine (DPPE)-
PEG2000 and [3H]-1,2-dimyristyl-sn-glycero-3-phos-
phoethanolamine (DMPE)-PEG2000 which were ob-
tained from Northern Lipids (Vancouver, BC, Can-
ada). The [3H]cholesterylhexadecyl ether (CHE) and
[14C]CHE were from NEN Life Science Products
(Boston, MA, USA). Cholesterol and ellagic acid
were purchased from Sigma-Aldrich Canada (Oak-
ville, ON, Canada). Bio-Gel A-15m size exclusion
gel was obtained from Bio-Rad (Mississauga, ON,
Canada).
2.2. Preparation of various liposomes
Lipids were dissolved in chloroform solution and
subsequently dried under a stream of nitrogen gas.
The resulting lipid ¢lm was placed under high vac-
uum for a minimum of 2 h. For making ‘heavy’
multilamellar liposomes (MLVs), the lipid ¢lm (egg
phosphatidylcholine (EPC)/Chol 55:45) was hy-
drated in 300 mM sucrose to a concentration of
100 mg/ml at 65‡C with vortex mixing. The resulting
preparation was centrifuged at 1600Ug for 10 min in
Eppendorf tubes, and the bottom sucrose layer was
removed with a 1 cm3 syringe and 20 gauge needle.
The MLVs were then washed three times with 0.5 ml
20 mM HEPES/150 mM NaCl bu¡er (pH 7.5) at
1600Ug for 10 min, and the pellet was resuspended
in 20 mM HEPES/150 mM NaCl bu¡er. The recov-
ery of MLVs in the pellet was always greater than
95%. For making large unilamellar liposomes
(LUVs), the lipid ¢lm was hydrated in 20 mM
HEPES/150 mM NaCl bu¡er (pH 7.5) or in citrate
300 mM (pH 4.0) at 65‡C. The resulting preparation
was frozen and thawed ¢ve times prior to extrusion
10 times through stacked polycarbonate ¢lters (Nu-
cleopore, Canada) at 65‡C with an extrusion appa-
ratus (Lipex Biomembranes, Vancouver, BC, Cana-
da). The resulting mean liposome diameter obtained
following extrusion was 100^120 nm as determined
by quasi-elastic light scattering using the Nicomp
submicron particle sizer model 370/270 [20,21].
2.3. Incorporation and retention of PEG-lipids in
liposomes
Incorporation of PE-PEGs in liposomes after hy-
dration and extrusion (thin ¢lm method) was deter-
mined by size exclusion chromatography. Brie£y,
liposomes labeled with trace levels of [14C]CHE and
tritiated PE-PEGs were applied to a 42 cmU1.3 cm
Bio-Gel A-15m column (50^100 mesh), and eluted
with 20 mM HEPES/150 mM NaCl bu¡er (pH 7.5)
at a £ow rate of 0.5 ml/min regulated by a peristaltic
pump. To elute under acidic conditions, citrate 300
mM solution (pH 4) was chosen as the elution bu¡er.
Aliquots (0.5 ml) from the 1 ml column fractions
were mixed with 5.0 ml Pico-£uor 15 scintillation
£uid (Packard Biosciences, The Netherlands) and
the level of radioactivity was determined using a
Packard scintillation counter model 1900 TR. To
determine the amount of PE-PEG transferred from
pure PE-PEG micelles to liposomes, 5 Wmol 10%
DOPS/DSPC/Chol liposomes were incubated with
micellar PE-PEGs (0.882 Wmol) with a ¢nal volume
of 0.4 ml for various times, and the resulting mixture
was fractionated on a 27 cmU0.7 cm Bio-Gel A-15m
column by gravity. The amount of PE-PEGs incor-
porated into liposomes by the micelle transfer meth-
od and by the thin ¢lm method was expressed in
Wmol PE-PEG/Wmol total lipid. The external PE-
PEG grafting density for the pegylated liposomes
prepared by micelle transfer method was estimated
as follows: mol% PE-PEG = 2U(molPEÿPEG/
moltotal lipid)U100%, based on the assumptions that
PEG-lipids are inserted only into the outer mono-
layer of the LUVs during the transfer process and
phospholipids are distributed equally between the
two monolayers.
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2.4. In vitro PEG-lipid transfer assay
Donor liposomes (LUVs) containing various types
of tritiated PEG-lipids were incubated with acceptor
MLVs (EPC/Chol) at 37‡C for various times at a
donor to acceptor mole ratio of 1:100. Donor
LUVs were separated from the acceptor MLVs by
centrifugation at 1600Ug for 10 min. The sample
was washed twice with 0.5 ml 20 mM HEPES/150
mM NaCl bu¡er at 1600Ug for 10 min. Both the
supernatant (donor LUVs) and the pellet (acceptor
MLVs) were collected for scintillation counting. Re-
covery, as determined by radioactivity, was over 95%
for donor and acceptor liposomes, respectively.
2.5. In vitro clotting time assay
This assay was based on the activated partial
thromboplastin time. An ellagic acid solution was
used freshly prepared and diluted in 20 mM
HEPES/150 mM NaCl bu¡er. Human citrated plas-
ma (50 Wl) was preincubated with 1035 M ellagic acid
(50 Wl) and liposomes (50 Wl) for 2 min at 37‡C.
Calcium was then added to initiate the clotting reac-
tion, and the mixture was gently shaken. The time at
which the mixture changed from a liquid to a viscous
gel was recorded, and was noted as the time for the
clotting reaction to be completed.
2.6. Correlation of PEG surface density and inhibition
of clotting activity
Correlation of PEG surface density and the per-
cent inhibition of clotting activity was derived from
data in Figs. 2A and 3B. The calculations were de-
scribed using DMPE-PEG as the example. The
DMPE-PEG levels at 0 and 24 h were 0.1048 and
0.0650 Wmol/Wmol lipid, respectively. Therefore, the
total DMPE-PEG loss was 0.0398 Wmol/Wmol lipid.
Assume there was 1 Wmol lipid and the phospholip-
ids were distributed equally between the two mono-
layers [22], the amount of DMPE-PEG on the outer
monolayer was equal to 0.0524 Wmol. Assume that
only DMPE-PEG on the outer monolayer were
available for transfer, the amount of DMPE-PEG
remaining on the outer monolayer was 0.0126
Wmol. The surface density of DMPE-PEG on the
outer monolayer was calculated as follows: surface
density (in mol%) = 0.0126 Wmol PEG/0.5 Wmol lip-
idU100% = 2.52. The same calculations were con-
ducted for DPPE-PEG. The percent inhibition of
clotting activity (from Fig. 3B) was then correlated
with the surface density of each of the PE-PEGs
(derived from Fig. 2A). Since the levels of DSPE-
PEG in the 10% DOPS LUVs were relatively con-
stant, indicating a very small amount of PE-PEG has
desorbed from the LUVs, the DSPE-PEG levels at
t = 0 h and 24 h were correlated with the correspond-
ing percent inhibition of clotting activity directly.
2.7. Plasma pharmacokinetics and tissue distribution
of liposomes
Liposomes, labeled with traces of [14C]CHE and
various [3H]PEG-lipids, were injected via the lateral
tail vein into 20^22 g female Balb/c mice. The total
lipid dose was 50 mg/kg with an injection volume of
200 Wl. At various times after liposome injection, 25
Wl blood was collected into microcapillary tubes pre-
rinsed with 200 mM EDTA solution by nicking the
tail vein. The blood was then added to 200 mM
EDTA solution (200 Wl) and centrifuged at 1000Ug
for 10 min. Aliquots of the supernatant were count-
ing directly in 5 ml Pico-£uor 40 scintillation £uid
(Packard Biosciences). At 4 and 24 h, three mice
were terminated by CO2 asphyxiation. Blood was
collected by cardiac puncture, and was placed into
EDTA-coated microtainer collection tubes (Becton-
Dickinson). After centrifuging the blood samples for
15 min at 1000Ug, plasma was isolated and visually
showed no hemolysis. Aliquots of the plasma ob-
tained were counted directly in 5.0 ml scintillation
£uid. Liver, spleen and lungs were harvested at 4
and 24 h to determine liposome accumulation in
these organs. Brie£y, 0.5 ml Solvable (Packard Bio-
Science) was added to whole organs (spleen and
lungs) or 50% w/v tissue homogenate (liver), and
the mixture was incubated at 50‡C overnight. After
cooling to room temperature, 50 Wl EDTA 200 mM,
200 Wl hydrogen peroxide 30%, and 25 Wl HCl 10 N
were added, and the mixture was incubated for 1 h at
room temperature. The mixture was added with 5.0
ml Pico-£uor 40 scintillation £uid and counted 24 h
later. It should be noted that all of the in vivo studies
were completed using protocols approved by the
University of British Columbia’s Animal Care Com-
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mittee. These studies met or exceeded the current
guidelines of the Canadian Council of Animal
Care. Pharmacokinetic parameters were calculated
using the software WinNonlin version 1.5.
3. Results
3.1. Kinetics of PE-PEG insertion into PS liposomes
from micelle addition
The incorporation of various PE-PEGs into neu-
tral and PS containing liposomes can be achieved
using two di¡erent methods. In one procedure of
incorporation, PE-PEGs were added as a separate
micelle solution to pre-formed liposomes (micelle
transfer method). The transfer of various PE-PEG
from micelles into PS containing liposomes as a func-
tion of time is shown in Fig. 1. Pure PE-PEG mi-
celles were added to pre-formed 10% DOPS contain-
ing liposomes to achieve a ¢nal concentration of
2.205 mM, which was above the CMC reported for
DSPE-PEG2000 (CMC of 2.2^10.8 WM [15]). At a PE-
PEG to liposome mole ratio of 0.176:1, not all of the
PE-PEGs were transferred into the PS containing
liposomes, and any unincorporated PE-PEG was
separated from the liposomes with Bio-Gel A-15m
column according to established procedures [9]. Mix-
ing PE-PEG micelles with liposomes did not have
any signi¢cant e¡ect on liposome size, which re-
mained in the range of 100^120 nm during the 24 h
incubation period with the PE-PEG micelles. After
4 h, only 0.012 Wmol DSPE-PEG2000 has been in-
serted into 1 Wmol 10% DOPS/DSPC/Chol lipo-
somes, as compared to 0.038 Wmol DMPE-PEG2000
and 0.045 Wmol DPPE-PEG2000. After 24 h, the
transfer of DMPE-PEG2000 and DPPE-PEG2000
into the 10% DOPS liposomes was almost complete.
The amounts of DMPE-PEG2000 and DPPE-PEG2000
transferred into 10% DOPS liposomes after 24 h
were 0.045 and 0.056 Wmol PE-PEG/Wmol total lipid,
respectively. The transfer of DSPE-PEG2000 into 10%
DOPS liposomes did not reach a similar level of
0.058 Wmol PE-PEG/Wmol total lipid until after 72 h.
3.2. Incorporation of PE-PEGs into PS and neutral
liposomes
The second procedure of PE-PEG incorporation
involved the addition of PE-PEGs to the lipid mix-
ture before making the dried lipid ¢lm for hydration
(thin ¢lm method). The pegylated liposomes pro-
duced by the thin ¢lm method would have an ap-
proximately equal distribution of the PE-PEGs in the
inner and outer monolayer [23], whereas PE-PEG
incorporation from addition of micelles results in
asymmetric PE-PEG distribution, where the PE-
PEGs are found exclusively in the outer monolayer
[11,24]. Table 1 summarizes the results of PEG-lipid
incorporation into liposomes by the two di¡erent
methods. The incorporation of DPPE- and DSPE-
PEG2000 into 10% DOPS/DSPC/Chol and DSPC/
Chol liposomes was approx. 14 mol% using the
thin ¢lm method. This is re£ected by the near quan-
titative (s 90%) incorporation of the PEG-lipids into
the liposomes. These results are consistent with pre-
vious studies by Kenworthy et al. and Hristova et al.
[25^27]. The incorporation of DMPE-PEG2000 into
10% DOPS/DSPC/Chol liposomes was less e⁄cient
compared to that of DPPE- and DSPE-PEG2000,
Fig. 1. Time course for DMPE-PEG2000 (R), DPPE-PEG2000
(b) and DSPE-PEG2000 (F) transfer from micelles into 10%
DOPS/DSPC/Chol liposomes at 37‡C. The inset highlights dif-
ferences in the rates of PE-PEG transfer over the ¢rst 4 h. The
amount of PEG-lipids transferred into liposomes is expressed as
Wmol PE-PEG per Wmol total lipid with each data point repre-
senting a single determination except at 24 h where the amount
of PEG-lipid transferred was determined in triplicates as de-
scribed in Section 2.
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where the liposomes after hydration and extrusion
contained 10.5 mol% DMPE-PEG2000 (Table 1).
This lower level of PEG-lipid incorporation was re-
£ected by a peak of free micellar DMPE-PEG2000
observed in the column elution pro¢le (data not
shown). Similarly, incorporation of DMPE-PEG2000
into DSPC/Chol liposomes was lower than the other
two types of PEG-lipids.
The PE-PEGs used in the present studies were
conjugated through a carbamate linkage that imparts
a net negative charge on the phosphate moiety at
physiological pH [28,29]; thus, the negative surface
charge on PS could potentially impede the incorpo-
ration of DMPE-PEG2000 into the PS containing
liposomes due to charge repulsion. We examined
the e¡ect of protonating the carboxyl moiety on PS
on DMPE-PEG2000 incorporation. At pH 4.0, ap-
prox. 97% of the carboxylate PS head groups are
protonated (based on pK = 5.5 [30]), and this led to
a modest yet statistically signi¢cant increase in the
incorporation of DMPE-PEG2000 into 10% DOPS/
DSPC/Chol liposomes from 10.5 mol% to 12.3
mol%, which was similar to that obtained with neu-
tral DSPC/Chol liposomes (12.0 mol%, see Table 1).
The incorporation of PE-PEGs into 10% DOPS/
DSPC/Chol liposomes by the micelle transfer method
described in Section 3.1 is also summarized in Table
1. The values reported for PE-PEG incorporation
using the micellar transfer method were PE-PEG lev-
els observed in the 10% DOPS liposomes after 24 h
for DMPE-PEG2000 and DPPE-PEG2000 and after 72
h for DSPE-PEG2000, time points where the transfer
process achieved s 90% of the estimated maximum.
Assuming that PEG-lipids were inserted only into the
outer monolayer of the LUVs during the transfer
process and phospholipids were distributed equally
between the two monolayers [11,24], the amount of
PEG-lipids transferred to the liposomes was ¢rst cal-
culated as mole percentage of total lipid, and this
value was then multiplied by two to approximate
the PEG-lipid density in the outer monolayer which
was equivalent to that achieved when preparing the
Table 1
Incorporation of various PEG-lipids into PS and neutral liposomesa
10% DOPS/DSPC/Chol DSPC/Chol
Wmol PE-PEG/Wmol total lipid mol% Wmol PE-PEG/Wmol total lipid mol%
Thin ¢lm method
DMPE-PEGb2000 0.105 þ 0.006 10.5
d;e 0.120 þ 0.009 12.0d
DMPE-PEG2000 (pH 4) 0.123 þ 0.003 12.3d
DPPE-PEG2000 0.132 þ 0.001 13.2e 0.139 þ 0.009 13.9
DSPE-PEG2000 0.140 þ 0.003 14.0 0.144 þ 0.004 14.4
Micelle transfer methodc
DMPE-PEGb2000 0.045 þ 0.002 9.08
e
DPPE-PEG2000 0.056 þ 0.003 11.2e
DSPE-PEG2000 0.058 (72 h) 11.7
aReported values represent means of three independent determinations and the standard deviations. Statistical analysis was performed
using ANOVA and Newman^Keuls test with P6 0.05.
bDMPE-PEG2000 was incorporated into 10% DOPS/DSPC/Chol liposomes hydrated at pH 7.5 and 4.0. Other PEG-lipids were incor-
porated into liposomes hydrated at pH 7.5.
cThe 10% DOPS/DSPC/Chol liposomes were incubated with PE-PEG micelles for 24 h (DMPE-PEG2000 and DPPE-PEG2000) or 72 h
(DSPE-PEG2000). The mixture was separated on Bio-Gel A-15m column as described in Section 2 to determine the amount of PEG-
lipids incorporated into the liposomes by the micelle transfer method, which was calculated as follows: mol% PE-
PEG = 2U(molPEÿPEG/moltotal lipid)U100% to re£ect the PE-PEG density on the outer monolayer, based on the assumptions that PE-
PEG are inserted only into the outer monolayer of LUVs during the transfer process and phospholipids are distributed equally be-
tween the two monolayers.
dIncorporation of DMPE-PEG2000 in 10% DOPS liposomes was statistically di¡erent from that in DSPC/Chol liposomes and from
that incorporated at pH 4.
eIncorporation of DMPE-PEG2000 in 10% DOPS liposomes by the thin ¢lm method was not statistically di¡erent from that incorpo-
rated by the micellar transfer method, while incorporation of DPPE-PEG2000 in 10% DOPS liposomes by the thin ¢lm method was
statistically di¡erent from that incorporated by the micellar transfer method.
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liposomes by the thin ¢lm method (see Table 1). The
external grafting density of DMPE-PEG2000 in 10%
DOPS liposomes was comparable using the two dif-
ferent methods. However, DPPE-PEG2000 and
DSPE-PEG2000 had slightly lower yet statistically sig-
ni¢cant external grafting densities in the outer mono-
layer of 10% DOPS liposomes using the micelle
transfer method as compared to the thin ¢lm meth-
od. The grafting densities achieved in the outer
monolayer for DPPE-PEG2000 and DSPE-PEG2000
were 11 and 12 mol% respectively using the micelle
transfer method, as compared to 13 and 14 mol%
respectively using the thin ¢lm method.
3.3. Kinetics of PE-PEG transfer from neutral and
anionic LUVs into MLVs
When liposomes are injected intravenously, mem-
branes from the vascular endothelium and other cel-
lular components in the bloodstream constitute a
large lipid pool that may interact with liposome
membranes, leading to possible interbilayer exchange
of lipids. In order to model this, the loss of various
PE-PEGs from neutral DSPC/Chol and PS contain-
ing LUVs was examined by incubating the LUVs
with a 100-fold molar excess of EPC/Chol MLVs.
The MLVs provided a lipid pool to accept the
PEG-lipids when transferring out of the LUVs (see
Fig. 2). A rapid decrease in DMPE-PEG2000 mem-
brane content was observed in both 10% DOPS lipo-
somes (Fig. 2A) and neutral DSPC/Chol liposomes
(Fig. 2B), with approx. 40% of DMPE-PEG2000
transferred out of the two types of liposomes within
15 min following the addition to the MLVs.
As the acyl chain length of the lipid anchor in-
creased from 14 carbons (DMPE) to 18 carbons
(DSPE), the rate of transfer of the PEG-lipids from
LUVs to MLVs was reduced such that the level of
DSPE-PEG2000 in 10% DOPS liposomes and in
DSPC/Chol liposomes remained relatively constant
over 24 h. This observation is consistent with results
from previous studies where the rate of PEG-lipid
transfer was decreased with increasing acyl chain
length [11^14]. Desorption of various PE-PEGs out
of the LUVs in the absence of MLVs under similar
conditions was negligible, with no micellar PE-PEGs
detected in fractions isolated following column chro-
matography (data not shown). It is interesting to
note that the amount of DPPE-PEG2000 transferred
out from 10% DOPS LUVs was higher than that of
DSPC/Chol LUVs, with 55% of DPPE-PEG2000 re-
maining in 10% DOPS liposomes after 24 h com-
pared to 85% in DSPC/Chol liposomes.
3.4. Regulation of membrane reactivity by
exchangeable PE-PEGs
Since protection of the lipid membrane surface
from protein and cellular binding is dependent on
Fig. 2. Time course for DMPE-PEG2000 (R), DPPE-PEG2000
(b) and DSPE-PEG2000 (F) transferred from 10% DOPS/DSPC/
Chol LUVs (A) or DSPC/Chol LUVs (B) to EPC/Chol MLVs
at 37‡C. Data points were determined in triplicate using the in
vitro PE-PEG transfer assay as described in Section 2, and the
error bars represent standard deviations.
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the retention of the PEG polymer barrier on the
membrane surface, the transfer of PEG-lipids into
or out of liposomes should also modulate the reac-
tivity of a biologically active membrane surface
which is capable of eliciting protein binding reac-
tions. In this study, the control of surface reactivity
of PS containing liposomes by PE-PEGs was eval-
uated by monitoring the clotting activity of 10%
DOPS liposomes at various times following PE-
PEG insertion and desorption. The transfer of micel-
lar DMPE-PEG2000 and DPPE-PEG2000 into 10%
DOPS liposomes resulted in rapid inhibition of clot-
ting activity (Fig. 3A). The percent inhibition of clot-
ting achieved following the incubation of PS lipo-
somes with micellar DMPE-PEG2000 and DPPE-
PEG2000 reached levels of 65% and 92% within 1 h,
respectively. In contrast, the transfer of micellar
DSPE-PEG2000 into 10% DOPS liposomes was
slow, and this resulted in much slower generation
of clotting activity inhibition, with only 8% inhibi-
tion achieved after 1 h. It is of interest to note that
the inhibition of clotting activity achieved 1 h follow-
ing the insertion of DPPE-PEG2000 was higher than
that achieved using DMPE-PEG2000 even though the
level of the DPPE-PEG2000 present in the 10% DOPS
liposomes was lower than that of DMPE-PEG2000
(compare Figs. 1 and 3A).
Next, the clotting activity of 10% DOPS liposomes
containing various types of PEG-lipids was examined
as the PEG-lipids were transferring out of the lipo-
somes (Fig. 3B). The transfer of approx. 40%
DMPE-PEG2000 out of 10% DOPS liposomes within
15 min resulted in a dramatic decrease in the inhibi-
tion of clotting activity from 67% to 18%. In con-
trast, the percent inhibition of clotting activity for
DSPE-PEG2000 remained constant for 24 h. This is
consistent with the data presented in Fig. 2B which
indicates that DSPE-PEG2000 is not readily lost from
the PS liposomes. For DPPE-PEG2000 which has a
rate of transfer that is intermediate between those of
DMPE-PEG2000 and DSPE-PEG2000, the inhibition
of clotting activity gradually decreased from 99% to
45% within 8 h (Fig. 3B).
Fig. 4 presents a composite of blood clotting ac-
tivity obtained as a function of the PEG-lipid con-
tent in 10% DOPS liposomes derived from the vari-
ous systems studied. Results from this study have
demonstrated a trend which re£ects a dependence
Fig. 3. Regulation of the clotting activity of 10% DOPS/DSPC/
Chol liposomes incorporated with various PE-PEGs by the mi-
celle transfer method (A) or by the thin ¢lm method (B). Panel
A shows the % inhibition of clotting activity as DMPE-PEG2000
(R), DPPE-PEG2000 (b) or DSPE-PEG2000 (F) transferred into
the 10% DOPS liposomes from micelles over 24 h. Panel B
shows the % inhibition of clotting activity as DMPE-PEG2000
(R), DPPE-PEG2000 (b) and DSPE-PEG2000 (F) transferred out
from the 10% DOPS liposomes into EPC/Chol MLV over 24 h.
The % inhibition of clotting activity was calculated as follows:
% inhibition = (tPEG3tPS)/(tBlank3tPS)U100, where t represents
the clotting time of each type of liposome as determined by the
in vitro clotting time assay. Data points were determined in
triplicate, and the error bars represent standard deviations.
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of the inhibition of clotting on the PE-PEG surface
density in the DOPS membrane. As the PEG surface
density increased in the DOPS membrane, it resulted
in higher percent inhibition of clotting activity. Re-
sults from a previous study also demonstrated a sim-
ilar trend where inhibition of clotting activity de-
pends on the PEG surface density [9].
3.5. E¡ect of exchangeable PEG-lipids on the plasma
levels of PS and neutral liposomes after
intravenous injection
To examine the e¡ect of PE-PEG transfer on the
plasma elimination pro¢les of PS containing LUVs
and DSPC/Chol LUVs, these two types of liposomes
with various PE-PEGs incorporated at s 10 mol%
were injected into mice, and plasma liposome con-
centrations were determined by monitoring a non-
exchangeable lipid label, [14C]CHE [31] (see Fig. 5).
The rapid transfer of DMPE-PEG2000 out of both
types of liposomes resulted in rapid removal of lipo-
somes from circulation, with approx. 10% and 35%
of the injected liposomal lipid remaining in plasma
after 1 h for 10% DOPS liposomes and DSPC/Chol
liposomes, respectively. The plasma levels of 10%
DOPS liposomes and DSPC/Chol liposomes contain-
ing the slowly exchanged DSPE-PEG2000 were much
higher, with 66% and 82% of the liposomal lipid
remaining in the plasma after 1 h, respectively. After
24 h, the plasma liposome levels for these systems
were 10% and 30%, respectively (Fig. 5). The plasma
elimination pro¢le of 10% DOPS liposomes contain-
Fig. 4. The % inhibition of clotting activity as a function of
PEG-lipid level in 10% DOPS/DSPC/Chol liposomes. Data
points represent the % inhibition of clotting activity and the
PE-PEG level in the 10% DOPS/DSPC/Chol liposomes before
or after 24 h incubation with the EPC/Chol MLV (derived
from Figs. 2A and 3B). The 10% DOPS liposomes were made
with DMPE-PEG2000 (R), DPPE-PEG2000 (b) or DSPE-
PEG2000 (F) incorporated by the thin ¢lm method. Error bars
represent standard deviations.
Fig. 5. The e¡ect of DMPE-PEG2000 (R), DPPE-PEG2000 (b)
and DSPE-PEG2000 (F) on the plasma elimination of 10%
DOPS/DSPC/Chol liposomes (A) and DSPC/Chol liposomes
(B). Plasma levels of the liposomal lipids were expressed as per-
centages of the amount of liposomal lipids injected. Three Balb/
c mice were used for each data point, and the error bars repre-
sent the standard errors.
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ing PE-PEGs was similar for systems incorporating
DPPE-PEG2000 and DMPE-PEG2000. This is in con-
trast to the results obtained with neutral DSPC/Chol
liposomes where DPPE-PEG2000 containing systems
were removed from the bloodstream much slower
than DMPE-PEG2000 liposomes (32% vs. 2% remain-
ing in plasma, respectively, after 4 h). This PS e¡ect
was re£ected by the fact that for liposomes prepared
with the same amount of DPPE-PEG2000, 6% of the
injected liposomes remained in plasma for DSPC/
Chol liposomes compared to 6 0.5% for 10%
DOPS liposomes after 24 h.
The amount of PE-PEGs remaining in plasma as a
percentage of the PEG-lipid injected was also moni-
tored in order to correlate liposome elimination
properties with retention of the PEG-lipids in the
liposomes. Fig. 6 demonstrates that the plasma elim-
ination of the three PEG-lipids studied followed the
same trend as that of the liposomal lipids where
DMPE-PEG2000 itself and the liposomes containing
this PEG-lipid had the fastest removal from the
bloodstream. DSPE-PEG2000 and the liposomes con-
taining this PEG-lipid were removed most slowly
from circulation. After 24 h, the plasma levels of
DSPE-PEG2000 were 4-fold and 10-fold higher than
those of DMPE-PEG2000 in 10% DOPS liposomes
and DSPC/Chol liposomes respectively. It is interest-
ing to note that the relative amount of PE-PEG in
the plasma was higher than the relative plasma levels
for liposomes when these liposomes were eliminated
rapidly from bloodstream. For instance, the percent-
age of DMPE-PEG2000 remaining in plasma at 24 h
for both 10% DOPS liposomes and DSPC/Chol lipo-
somes was approx. 2% compared to 6 0.5% of lipo-
somal lipid remaining for the two types of liposomes,
as determined from [14C]CHE. Since DMPE-PEG2000
is able to transfer out of liposomes rapidly, it may
possibly interact with plasma components that act as
an acceptor for DMPE-PEG2000, leading to longer
circulation times of the PEG-lipid. This is supported
by a previous ¢nding that DMPE-PEG2000 can ex-
change into the plasma lipoprotein pool [32].
4. Discussion
In the development of thrombogenic PS liposomes
for selective thrombosis in tumor blood vessels, con-
trolled exposure of the thrombogenic surface is cru-
cial and this requires transient shielding of the lipo-
somal PS surface. Retention of a surface grafted
PEG polymer coating is necessary for the protection
of the thrombogenic PS liposome surface in the gen-
eral circulation. However, the PEG polymer coating
on the PS liposome surface may prevent interactions
with the clotting factors and the initiation of blood
coagulation once they have localized in the tumor
Fig. 6. Plasma levels of DMPE-PEG2000 (R), DPPE-PEG2000
(b) and DSPE-PEG2000 (F) in Balb/c mice expressed as percen-
tages of the amount of PEG-lipids injected, with 10% DOPS/
DSPC/Chol (A) and DSPC/Chol (B) as carriers for the PEG-
lipids. Three mice were used for each data point, and the error
bars represent the standard errors.
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vasculature. Controlled loss of the PEG coating is
therefore necessary to trigger the blood coagulation
reactions mediated by the PS membrane surface
within the tumor blood vessels. Indeed, current
trends in designing liposomes with surface grafted
PEG are to achieve: (1) temporary stabilization of
liposomes in circulation to allow adequate accumu-
lation in target site, and (2) subsequent transforma-
tion of liposomes to a reactive or unstable form to
facilitate target cell interaction/fusion and content
release through the loss of PEG polymer
[11,14,18,19,33^35]. Furthermore, in designing pegy-
lated liposomes, it is possible to control membrane-
dependent enzymatic activity by controlling the ac-
cess of proteins/enzymes to the liposome surface via
inclusion of appropriate levels of the surface grafted
PEG polymer coating [36,37]. In this study, we have
demonstrated the ability to control the surface reac-
tivity of PS containing membranes toward high af-
¢nity clotting factors in a time-dependent fashion
through the use of exchangeable PE-PEGs. This en-
hances our understanding of how to design lipo-
somes for inducing tumor selective thrombosis.
Several features have been identi¢ed in governing
the transfer rate of PEG-lipids, including the head
group and the acyl chain of PEG-lipids, the lipo-
somal lipid composition and the concentration of
the acceptor membrane [12,13,38^40]. The hydro-
philic PEG polymer (MW 2000) on the various lipid
anchors used in this study was conjugated to the
amino group on PE, resulting in the generation of
a negatively charged PE-PEG at physiological pH
[28,29]. The negative charge on PE-PEGs has a mod-
est e¡ect on reducing DMPE-PEG2000 membrane in-
corporation into the negatively charged 10% DOPS
membrane. This is likely due to the charge repulsion
between the DMPE-PEG2000 and DOPS head
groups. Although the e¡ect of the molecular weight
of the PEG polymer was not investigated in this
study, it has been documented that an increase in
the molecular weight of the PEG polymer would
lead to an increase in the desorption rate of PEG-
lipids from vesicles [13].
Among the three types of PE-PEGs used, DMPE-
PEG2000 was observed to have the lowest incorpora-
tion into both neutral and PS containing liposomes
and the fastest rate of transfer into and out of the
liposomes. This result is consistent with previous
studies [11^14]. Considering the acyl chain lengths
of DMPE-PEG2000 and of the remaining lipid com-
ponents (DSPC/Chol þ 10 mol% DOPS), formation
of packing defects in the lipid bilayer is probable
because of the four-carbon mismatch in the acyl
chain lengths [41,42]. These packing defects may
make the incorporation of DMPE-PEG2000 into the
liposomes less favorable, thus limiting the amount of
DMPE-PEG2000 that can be incorporated into lipo-
somes. Alternatively, the smaller length/width axial
ratio of this PEG-lipid may result in a more pre-
ferred partitioning into highly curved micellar struc-
tures [24,43]. Desorption of lipids or lipid conjugates
involves the formation of a transition state which
entails a signi¢cant displacement of the acyl chain
into the aqueous phase [44]. This requires energy to
disrupt the lipid^lipid van der Waals interactions and
the hydrogen-bonded water to accommodate the lip-
id acyl chain in the aqueous phase. Thus, increasing
the hydrophobicity by extending the acyl chain of the
lipid anchor would make the desorption of PEG-lip-
ids energetically more unfavorable.
Under in vitro conditions in the absence of an ac-
ceptor membrane, PE-PEGs did not desorb from
10% DOPS LUVs or from DSPC/Chol LUVs. The
presence of an acceptor membrane is thus necessary
for the desorption of PEG-lipids from LUVs. In this
study, 20 mM MLVs were used in the in vitro trans-
fer assay, and under high acceptor vesicle concentra-
tions, it is possible to enhance the rate of PE-PEG
desorption. This may be due to an increase in the
collisional frequency of the pegylated LUVs and
the acceptor MLVs that may facilitate transfer of
the lipid [39,40]. Although fusion-mediated lipid
transfer has been suggested previously as an alterna-
tive means of PE-PEG transfer [45], our data do not
support this mechanism because recovery of the
LUVs in the supernatant, as determined by the
[14C]CHE lipid marker, was always s 95%. Given
that membrane^membrane contact can be inhibited
by surface grafted PEG polymer at 1^2 mol% [11],
fusion-mediated lipid transfer may be sterically hin-
dered in our case where PEG surface density was
elevated (s 10 mol%). Other possible mechanisms
whereby PE-PEG can be transferred into MLVs in-
clude direct transfer of the PE-PEG monomer or
transfer through the formation of intermediate PE-
PEG micelles or oligomers after desorption of the
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PE-PEG monomers from the LUV bilayer. The
MLVs in the in vitro PEG-lipid transfer assay act
as a lipid pool, which provides a large surface area
to accept the PEG-lipids as they are desorbing from
liposomes, similar to the large membrane surface
from the vascular endothelium and other cellular
components in the bloodstream. Another potential
PEG-lipid acceptor in vivo is the lipoprotein family
which is known to be involved in lipid transfer
[32,46]. Our data showed that the relative amount
of DMPE-PEG2000 in plasma was higher than that
for the liposomal lipids which were eliminated rap-
idly from the bloodstream. It is possible that DMPE-
PEG2000 was transferred to the lipoproteins, resulting
in longer circulation lifetimes.
Our in vivo data clearly demonstrated that the
negatively charged PS liposomes containing DMPE-
PEG or DPPE-PEG were eliminated from the blood-
stream more rapidly than the neutral DSPC/Chol
liposomes containing either of these PE-PEGs. It is
well documented that the plasma elimination of PS
containing liposomes is very rapid (s 90% of in-
jected dose within minutes) due in part to PS-medi-
ated plasma protein interactions with the liposome
surface and subsequent MPS recognition. As
DMPE-PEG and DPPE-PEG exchanged out of the
PS liposomes, PS would be exposed to the high bind-
ing a⁄nity plasma proteins. It is likely that the in-
teraction between the high a⁄nity plasma proteins
and PS liposomes (with a free energy of association
of about 39 kcal/mol for factor X [47]) may provide
additional energy to overcome the energy barrier for
PE-PEG desorption from PS membranes. This may
result in further PE-PEG loss from PS liposomes and
more PS being exposed to plasma proteins for inter-
actions.
In designing ‘transiently stabilized’ liposomes, it is
important to balance the necessity of achieving cir-
culation longevity for target accumulation, and the
importance of transforming the liposomes to a form
that is capable of initiating site-speci¢c reactions
such as drug release, cell fusion or selective access
of proteins. For pegylated liposomes, this balance
is dependent on the rate at which the grafted PEGs
desorb from the liposomes. In this study, we have
demonstrated that the membrane surface reactivity
of PS containing liposomes can be controlled in a
time-dependent fashion by using exchangeable
PEG-lipids of various acyl chain lengths. This has
greatly contributed to our development of liposomes
capable of triggering tumor site-speci¢c thrombosis.
For our intended application, PS containing lipo-
somes must also achieve tumor site-speci¢c accumu-
lation and localization of PS to minimize the poten-
Fig. 7. A schematic illustration of the thrombogenic PS liposomes targeted to over-expressed markers on the tumor vasculature.
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tial for disseminated intravascular coagulation (see
Fig. 7). We are currently conducting studies to target
these liposomes to tumor vasculature by conjugating
monoclonal antibodies speci¢c for antigen expressed
on endothelial cells of the tumor neovasculature. Re-
sults from this study have important implications in
the design of more sophisticated, multi-functional
liposomes for targeted drug delivery. Speci¢cally,
the amount and chemical attributes of steric stabiliz-
ing lipids for such liposomes may be signi¢cantly
di¡erent from those used for purposes of simply re-
ducing liposome elimination rates.
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